France,FR
Experienced business and science journalist. Expertise in biopharmacutical sector. I enjoy finding things out and writing them down.
Could a genetically engineered adenovirus really spark a simian revolution and make chimps our masters? BioPharma-Reporter.com looks at the 'science' of the 2011 movie "Rise of the Planet of the Apes." To date, chimp uprisings have been few, far between and - if one believes UK adverts from the 1970s - limited to the odd unruly tea party and damaged piano.
Scientists say the Chinese hamster genome published last month will help biomanufacturers develop better CHO cell lines. This BioPharma-Reporter.com timeline traces the hamster's journey from the deserts of China to the research labs of Harvard in the mid-50s and on to the manufacturing facilities of today's $125bn biomanufacturing industry.
Government-backing for a large-scale cell therapy centre is justified because it will help developers navigate the "valley of death" in which many early-phase projects fail says the team planning the new manufacturing hub.
Importing drugs and ingredients from the East is not a new idea, but did the practice start 2000 years ago in Judea? Gold, as at least one wise man knew, is always likely to be well received, particularly if the recipients in question are a young couple looking to upgrade to a penthouse manger with an en suite and view of Bethlehem's historic old town.
The end of the world is likely to have a negative impact on clinical trials according to research published in the journal of the Canadian Medical Association. The study - by researchers at the University of Ottawa in Canada - examined what impact an apocalypse coinciding with the end of the Mayan long count calendar on December 21 would have on survival outcomes in clinical trials.